Ann: Teva Launches Generic Version of Axiron in United States, page-10

First 10 Last

Share
Profile

Follow
Slogger

7,539 Posts.

696

06/09/17

09:44

Post #: 27024702
Share

Originally posted by piggybanks ↑

@Slogger
1) the Axiron stuff is fully paid for by Eli Lilly. Clinical trials, TV ads, sales marketing, regulatory submissions and legal appeals. 2 years ago Eli Lilly spent $150m on TV ads for instance.
2) I assume they won't win on appeal but I had an expert look at it and says it has a strong chance.
3) ironically they are doing other drugs as generics in the pipeline and the CEO has good experience here from Mayne Pharma
4) I think they will have to fund this legal work but I don't think it gets meaty on costs for another 2-4 years until there is a court hearing and you have to pay for experts etc.
5) Dividend cut to zero was dumb and means certain investors have to exit. They could afford $3m a year on dividend even if its token.
6) They have plenty of extra cash as when the decision to cut the dividend last year was made they have since had full freight of another $30m of cash flow. I am thinking going forward this will be only $5-10m in Axiron royalties.
7) Cost of pipeline R&D is $10-15m / year. They have at least 3 years of cash on this rough basis.
8) If they win the appeal it is party time because Eli Lilly will get a fully loaded account of profits but doesn't need to spend on marketing etc. Could be a $50m cash windfall for ACR
9) The pipeline of generics looks better than Mayne Pharma and its market cap is $1bn. This could be the upside for ACR in 3 years.
10) For these reasons I bought back in at $0.31

Expand

I guess unfortunately the ANN this morning may change some of the above comments.

ACR Price at posting: 26.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

SKS

SKS secures $20M for extension works on Melbourne data centre

EBR

EBR Systems' heart pacing device on-target to reach the US market

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

There are more pages in this discussion • 1 more message in this thread...

First 10 Last

Add ACR (ASX) to my watchlist

(20min delay)
Last 6.1¢		Change 0.000(0.00%)		Mkt cap ! $17.73M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
4	152642	5.9¢

Sellers (Offers)

Price($)	Vol.	No.
6.1¢	100089	2

View Market Depth

No.	Vol.	Price($)
4	152642	0.059
3	126241	0.058
2	100908	0.055
1	88000	0.054
1	197000	0.051

Price($)	Vol.	No.
0.061	100089	2
0.062	216145	2
0.063	100000	1
0.064	12500	1
0.065	130000	1

Last trade - 14.59pm 04/09/2024 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

Ann: Teva Launches Generic Version of Axiron in United States, page-10

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

SKS secures $20M for extension works on Melbourne data centre

EBR Systems' heart pacing device on-target to reach the US market

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Teva Launches Generic Version of Axiron in United States, page-10

Top Stories

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

SKS secures $20M for extension works on Melbourne data centre

EBR Systems' heart pacing device on-target to reach the US market

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News